Company intelligence / Profile preview

GreenLamp

United States

Ownership: Private
Development stage: Other

Overview

No product revenues generated as of December 2022; accumulated losses of $420.6 million since inception in 2008. First commercial products launched in 2025: Calantha (Colorado potato beetle bio-insecticide) and Norroa (varroa mite control).

Therapeutic areas: OncologyHematologyOtherInfectious Diseases
Modalities: RNA therapySmall interfering RNAmRNA-based drugsVaccine
Industry: Biotech

Partnerships

Bayer CropScience (technology transfer)Serum Institute of India (licensing agreement for mRNA products)Samsung Biologics (mRNA vaccine manufacturing)IAVI (COVID-19 vaccine deployment in Africa)Epivax Therapeutics (cancer vaccine collaboration)One Acre Fund (field trials in East Africa)Acuitas Therapeutics

Beyond the preview

Go deeper on GreenLamp.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GreenLamp.

Explore the full profile